The Use of Nonhuman Primate Models in HIV Vaccine Development

article has not abstract

Vyšlo v časopise: The Use of Nonhuman Primate Models in HIV Vaccine Development. PLoS Med 5(8): e173. doi:10.1371/journal.pmed.0050173
Kategorie: Guidelines and Guidance
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.0050173

Souhrn

article has not abstract

Zdroje

1. DesrosiersRC

2004

Prospects for an AIDS vaccine.

Nat Med

221

223

2. FeinbergMBMooreJP

2002

AIDS vaccine models: Challenging challenge viruses.

Nat Med

207

210

3. HaigwoodNL

2004

Predictive value of primate models for AIDS.

AIDS Rev

187

198

4. HuSL

2005

Non-human primate models for AIDS vaccine research.

Curr Drug Targets Infect Disord

193

201

5. JohnsonRP

2006

HIV pathogenesis and vaccine development.

Top HIV Med

6. KoffWCJohnsonPRWatkinsDIBurtonDRLifsonJD

2006

HIV vaccine design: Insights from live attenuated SIV vaccines.

Nat Immunol

7. LetvinNL

2006

Progress and obstacles in the development of an AIDS vaccine.

Nat Rev Immunol

930

939

8. LifsonJDMartinMA

2002

One step forwards, one step back.

Nature

415

272

273

9. MalkevitchNVRobert-GuroffM

2004

A call for replicating vector prime-protein boost strategies in HIV vaccine design.

Expert Rev Vaccines

S105

S117

10. RobinsonHLAmaraRR

2005

T cell vaccines for microbial infections.

Nat Med

S25

S32

11. ShiverJWFuTMChenLCasimiroDRDaviesME

2002

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Nature

415

331

335

12. CasimiroDRWangFSchleifWALiangXZhangZQ

2005

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag.

J Virol

15547

15555

13. WilsonNAReedJNapoeGSPiaskowskiSSzymanskiA

2006

Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239.

J Virol

5875

5885

14. WyandMSMansonKMontefioriDCLifsonJDJohnsonRP

1999

Protection by live, attenuated simian immunodeficiency virus against heterologous challenge.

J Virol

8356

8363

15. RobertsonMMehrotraDFitzgeraldDDuerrACasimiroD

2008

Efficacy results from the Step Study (Merck V520 Protocol 023/HVTN 502)—A phase II test-of-concept trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent vaccine [abstract 88LB].

15th Conference on Retroviruses and Opportunistic Infections; 3–6 February 2008; Boston, Massachusetts, United States of America. Available: http://www.hvtn.org/science/step_buch.html. Accessed 10 July 2008